207 related articles for article (PubMed ID: 23379516)
1. Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis.
Eriksson C; Rantapää-Dahlqvist S; Sundqvist KG
Scand J Rheumatol; 2013; 42(4):260-5. PubMed ID: 23379516
[TBL] [Abstract][Full Text] [Related]
2. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.
Nissinen R; Leirisalo-Repo M; Peltomaa R; Palosuo T; Vaarala O
Ann Rheum Dis; 2004 Jun; 63(6):681-7. PubMed ID: 15140775
[TBL] [Abstract][Full Text] [Related]
3. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression.
Aerts NE; De Knop KJ; Leysen J; Ebo DG; Bridts CH; Weyler JJ; Stevens WJ; De Clerck LS
Rheumatology (Oxford); 2010 Dec; 49(12):2264-72. PubMed ID: 20724433
[TBL] [Abstract][Full Text] [Related]
4. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis.
Odai T; Matsunawa M; Takahashi R; Wakabayashi K; Isozaki T; Yajima N; Miwa Y; Kasama T
J Rheumatol; 2009 Jun; 36(6):1158-65. PubMed ID: 19369458
[TBL] [Abstract][Full Text] [Related]
5. Blockage of TNF-α by infliximab reduces CCL2 and CCR2 levels in patients with rheumatoid arthritis.
Xia L; Lu J; Xiao W
J Investig Med; 2011 Aug; 59(6):961-3. PubMed ID: 21527853
[TBL] [Abstract][Full Text] [Related]
6. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
7. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
[TBL] [Abstract][Full Text] [Related]
8. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
9. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
[TBL] [Abstract][Full Text] [Related]
10. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
11. The effect of infliximab on chemokines in patients with rheumatoid arthritis.
Torikai E; Kageyama Y; Suzuki M; Ichikawa T; Nagano A
Clin Rheumatol; 2007 Jul; 26(7):1088-93. PubMed ID: 17111092
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
13. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
[TBL] [Abstract][Full Text] [Related]
14. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.
Aeberli D; Seitz M; Jüni P; Villiger PM
Rheumatology (Oxford); 2005 Feb; 44(2):172-5. PubMed ID: 15509629
[TBL] [Abstract][Full Text] [Related]
15. Neutrophils of rheumatoid arthritis patients on anti-TNF-α therapy and in disease remission present reduced adhesive functions in association with decreased circulating neutrophil-attractant chemokine levels.
Dominical VM; Bértolo MB; Almeida CB; Garrido VT; Miguel LI; Costa FF; Conran N
Scand J Immunol; 2011 Apr; 73(4):309-18. PubMed ID: 21208248
[TBL] [Abstract][Full Text] [Related]
16. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.
Dahlqvist SR; Engstrand S; Berglin E; Johnson O
Scand J Rheumatol; 2006; 35(2):107-11. PubMed ID: 16641043
[TBL] [Abstract][Full Text] [Related]
17. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions.
Edrees AF; Misra SN; Abdou NI
Clin Exp Rheumatol; 2005; 23(4):469-74. PubMed ID: 16095114
[TBL] [Abstract][Full Text] [Related]
19. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab.
Toubi E; Kessel A; Mahmudov Z; Hallas K; Rozenbaum M; Rosner I
Ann N Y Acad Sci; 2005 Jun; 1051():506-14. PubMed ID: 16126991
[TBL] [Abstract][Full Text] [Related]
20. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
